UK expects to save 75% from adalimumab rivals

  
Generate a summary of this article
Listen to this article
Beta

Savings of around 75% on the cost of adalimumab are expected by the UK’s National Health Service (NHS) “after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug”. The NHS said it had “moved swiftly to drive strong competition between biosimilar manufacturers and the manufacturer of the originator brand, resulting in huge cost discounts”.

Savings of around 75% on the cost of adalimumab are expected by the UK’s National Health Service (NHS) “after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug”. The NHS said it had “moved swiftly to drive strong competition between biosimilar manufacturers and the manufacturer of the originator brand, resulting in huge cost discounts”.

“The deal should mean hospitals pay around a quarter of the more than £400 million (US$513 million) each year they...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

GB-Business-Free-Podcast-The Secret to Walking More: It’s Not Counting Steps - Clone

 
• By Nabil

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.